Peptide
BPC-157
Also known as
Body Protection Compound-157 · BPC 157 · BPC157 · PL 14736 · PL14736 · PL-10 (oral Bepecin trial code discussions) · Bepecin (research designation) · Stable gastric pentadecapeptide BPC 157 · Pentadeca arginate / PDA (arginate salt marketing name) · Arg-BPC / BPC-157 arginate (oral-stability form talk)
Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.
What it is
| Recovery and gut discussion | BPC-157 is a synthetic peptide people discuss for stubborn tendon or joint pain, injury recovery and gut symptoms. |
|---|---|
| Different forms | Capsules and injections have different formulations and reported amounts; equal labeled micrograms do not establish equal effects. |
Notes
BPC-157 is a synthetic peptide that people discuss for stubborn tendon and joint pain, injury recovery and gut symptoms. The appeal is getting back to normal movement or training. Community reports range from noticeable relief to no change, and some users stop because of unwanted effects.
Gut symptoms, especially in oral discussions. Capsule users discuss digestion and gut comfort, but oral reports also include joint and tendon goals. Capsules and injections have different formulations and reported amounts; equal labeled micrograms do not establish equal effects. My experience rates oral BPC157 on par or superior to injections (Personal report · Accessed 2026-09-30)
Source context — My experience rates oral BPC157 on par or superior to injections: Unverified formulation, dose changes and overlapping routes. Claimed serotonin mechanism not adopted.
What people notice
| Less pain and easier movement | Some shoulder, elbow and ankle accounts describe less pain or easier training. These self-assessments do not establish that damaged tissue has healed. |
|---|---|
| Gut comfort or no change | Some oral users describe improved gut comfort, sleep or exercise. Others report no benefit, including a 20-day BPC/TB blend account. |
| Reasons people stop | Positive accounts can also include nausea, palpitations, emotional detachment or disabling anxiety. |
Notes
Tendons, joints and old injuries. Shoulder, elbow and ankle accounts describe less pain or easier movement. Rest, physical therapy and changes in training often happen at the same time, so a better week cannot tell us which part helped. BPC-157 Log (Completed) (Personal report · Accessed 2026-09-30) · Oral BPC-157 experience (Community discussion · Accessed 2026-09-30)
Less pain in everyday movement. A shoulder log described less day-to-day pain and a return to a shoulder workout. An elbow account described recovering movement over a course. These are self-assessments, not scans or measurements of tissue repair. BPC-157 Log (Completed) (Personal report · Accessed 2026-09-30) · BPC-157 Cycle Duration and Time Off (Community discussion · Accessed 2026-09-30)
Better gut comfort or easier training. Some oral users describe improved gut symptoms, sleep or ability to exercise. Others notice nothing. The useful comparison is the specific symptom and activity that changed, rather than a general claim that BPC “heals everything.” My experience rates oral BPC157 on par or superior to injections (Personal report · Accessed 2026-09-30) · Oral BPC-157 experience (Community discussion · Accessed 2026-09-30) · What to do if not seeing results from Bpc157 and tb500? (Personal report · Accessed 2026-09-30)
No change belongs beside the success stories. One person reported no improvement in a foot ligament injury or wrist sprain after 20 days of a BPC/TB blend. Replies suggested more time or a different product, but neither explanation was established. A null result is not automatically a dosing mistake. What to do if not seeing results from Bpc157 and tb500? (Personal report · Accessed 2026-09-30)
Improvement can come with a reason to stop. The shoulder-log author described improvement alongside nausea, palpitations and feeling detached. Another user reported injury and gut improvement but stopped for disabling anxiety while also taking an SSRI. That co-use does not prove a specific interaction. BPC-157 Log (Completed) (Personal report · Accessed 2026-09-30) · My experience with BPC-157 (Personal report · Accessed 2026-09-30)
Source context — BPC-157 Log (Completed): Uncontrolled subjective report; older product, concurrent illness, prior derealization and changing training. Relative page timestamp not converted to an exact date.
Source context — Oral BPC-157 experience: Advertising influenced purchase; OP also used enclomiphene. The OP writes an ambiguous 500mg label, so that amount is not silently corrected to mcg or included in numerical answers. No vendor endorsement.
Source context — BPC-157 Cycle Duration and Time Off: Later TB addition and oral maintenance confound persistent outcomes. The approximately four-hour immediate relief in post 8 is attributed to TB, not BPC, and is excluded from BPC duration. Promotion/procurement replies not reproduced.
Source context — My experience rates oral BPC157 on par or superior to injections: Unverified formulation, dose changes and overlapping routes. Claimed serotonin mechanism not adopted.
Source context — What to do if not seeing results from Bpc157 and tb500?: Blend use, unverified identity, no objective injury assessment. Replies' dose/vendor suggestions not adopted.
Source context — My experience with BPC-157: SSRI co-use and subjective symptoms; cannot establish interaction or causation. Relative dates retained without a fabricated calendar date.
Doses people talk about
| Under-the-skin reports | 250–500 mcg total per day is the recurring band, once daily or divided. Inspected examples include 200 mcg once daily and 250 mcg twice daily. |
|---|---|
| Oral charts and one account | Charts list 200–500 mcg per dose once or twice daily. A separate arginate-capsule account reports 700 mcg once daily, then twice daily, totaling 1,400 mcg/day. |
| Higher injection reports | 750–1,000 mcg total per day appears in chronic-tendon and post-operative notes; more does not establish greater benefit or a safe ceiling. |
| Nasal reports | Older notes include about 250–500 mcg per spray. That labeled amount is not equivalent to exposure from an injection. |
Notes
SubQ: 250–500 mcg total per day. This is the recurring band in the existing community record, once daily or divided. Inspected examples include 200 mcg once daily and 250 mcg twice daily—the latter totals 500 mcg a day. BPC-157 misinformation (Community discussion · Accessed 2026-09-30) · BPC-157 Log (Completed) (Personal report · Accessed 2026-09-30)
Oral: 200–500 mcg per dose, once or twice daily, in existing charts. Other accounts differ: one arginate-capsule user reported 700 mcg once daily, then twice daily (1,400 mcg/day). These are separate reports, not one interchangeable oral/injection range. My experience rates oral BPC157 on par or superior to injections (Personal report · Accessed 2026-09-30)
Higher SubQ reports: 750–1,000 mcg total per day. These appear in the existing chronic-tendon and post-operative notes. Higher amounts do not establish greater benefit or a safe ceiling.
Forms and labels create practical confusion. Acetate versus arginate, capsules versus sprays, and premixed versus separate vials are recurring debates. The existing notes include nasal reports around 250–500 mcg per spray; that labeled amount is not equivalent to SubQ exposure. Stability and absorption claims from sellers remain claims.
Source context — BPC-157 misinformation: Self-report and opinion; location comparisons uncontrolled. A separate responder, delsolrob, displays a sponsor affiliation. No fasting or local-delivery superiority adopted.
Source context — BPC-157 Log (Completed): Uncontrolled subjective report; older product, concurrent illness, prior derealization and changing training. Relative page timestamp not converted to an exact date.
Source context — My experience rates oral BPC157 on par or superior to injections: Unverified formulation, dose changes and overlapping routes. Claimed serotonin mechanism not adopted.
Half-life, onset & duration
| Felt onset | Some describe pain or movement changes after a few days; others first notice change at 2–3 weeks. One oral account describes calm after six hours and less pain after two days. |
|---|---|
| Felt duration | No dependable single-dose benefit duration is established. Most logs describe repeated daily use; some report lasting improvement and others continued or returning aches. |
| Half-life | About four hours circulates as a community claim without a measured human basis or specified route. Animal blood measurements do not establish human oral or injection clearance. |
Notes
A few days in some accounts; 2–3 weeks in others. An abdominal-injection account described forearm improvement after four days. An elbow user first noticed meaningful change in weeks 2–3. One oral arginate account described feeling calmer after six hours and less pain after two days. These are different outcomes, not a guaranteed onset window. BPC-157 misinformation (Community discussion · Accessed 2026-09-30) · BPC-157 Cycle Duration and Time Off (Community discussion · Accessed 2026-09-30) · My experience rates oral BPC157 on par or superior to injections (Personal report · Accessed 2026-09-30)
No dependable single-dose benefit duration in these reports. Most logs describe changes during repeated daily use. Some report lasting improvement; others describe aches returning after a switch or continued symptoms. A course lasting weeks is not proof that one dose works for that long. BPC-157 Log (Completed) (Personal report · Accessed 2026-09-30) · Oral BPC-157 experience (Community discussion · Accessed 2026-09-30) · BPC-157 Cycle Duration and Time Off (Community discussion · Accessed 2026-09-30) · What to do if not seeing results from Bpc157 and tb500? (Personal report · Accessed 2026-09-30)
About 4 hours is a circulated community estimate. It appears in T Nation discussion and a Reddit comment attributing it to a peptide book. Those posts do not supply a measured human clearance study or establish a route-specific half-life. Treat it as a community claim, not a verified human value. BPC-157 Detection Time? (Secondhand community claim · Accessed 2026-09-30) · Bpc-157 forever? (Secondhand community claim · Accessed 2026-09-30)
The measured figures in the original notes are animal results. The 2022 rat/dog study reported parent-peptide plasma half-lives of 15.2 minutes in rats given IV, 7.87–29.7 minutes in rats given IM, and 5.3 minutes in dogs given IV. IV is into a vein; IM is into muscle. These do not establish a human oral or SubQ value and are not used for the community quick answer above. He et al. — BPC-157 pharmacokinetics in rats and dogs (Animal context · Accessed 2026-09-30)
Source context — BPC-157 misinformation: Self-report and opinion; location comparisons uncontrolled. A separate responder, delsolrob, displays a sponsor affiliation. No fasting or local-delivery superiority adopted.
Source context — BPC-157 Cycle Duration and Time Off: Later TB addition and oral maintenance confound persistent outcomes. The approximately four-hour immediate relief in post 8 is attributed to TB, not BPC, and is excluded from BPC duration. Promotion/procurement replies not reproduced.
Source context — My experience rates oral BPC157 on par or superior to injections: Unverified formulation, dose changes and overlapping routes. Claimed serotonin mechanism not adopted.
Source context — BPC-157 Log (Completed): Uncontrolled subjective report; older product, concurrent illness, prior derealization and changing training. Relative page timestamp not converted to an exact date.
Source context — Oral BPC-157 experience: Advertising influenced purchase; OP also used enclomiphene. The OP writes an ambiguous 500mg label, so that amount is not silently corrected to mcg or included in numerical answers. No vendor endorsement.
Source context — What to do if not seeing results from Bpc157 and tb500?: Blend use, unverified identity, no objective injury assessment. Replies' dose/vendor suggestions not adopted.
Source context — BPC-157 Detection Time?: Four-hour half-life stated as supposed, with no human PK source or route. Drug-test clearance advice explicitly rejected.
Source context — Bpc-157 forever?: Book not inspected; attribution does not authenticate the book or a measured human half-life. No no-break safety inference.
Source context — He et al. — BPC-157 pharmacokinetics in rats and dogs: Parent-peptide plasma elimination; rat/dog IV/IM only. Excluded from all five community quick-answer sections.
Cycles people discuss
| Reported blocks | Existing patterns include 2–4 weeks for shorter injury blocks and 4–8 weeks or longer for chronic complaints. Inspected accounts include six weeks and two or three months. |
|---|---|
| No agreement on breaks | Reports mention 2–4 weeks off, equal time off, stopping when symptoms settle or five days on/two off. Other posters dispute needing a break. |
Notes
2–4 weeks for shorter injury blocks; 4–8 weeks or longer for chronic complaints. These are the existing community patterns. One inspected elbow account ran six weeks; another forum user described two or three months. They do not establish an optimal or safe course length. BPC-157 Cycle Duration and Time Off (Community discussion · Accessed 2026-09-30)
Breaks vary: 2–4 weeks off, equal time off, or stopping when symptoms settle. A forum post describes four weeks on followed by two to four off. Other threads disagree about needing a break at all. Five days on/two off also appears; no shared rule settles the disagreement. BPC 157, formerly written by me! For all injured athletes! (Community opinion · Accessed 2026-09-30) · BPC-157 Cycle Duration and Time Off (Community discussion · Accessed 2026-09-30) · Bpc-157 forever? (Secondhand community claim · Accessed 2026-09-30)
Source context — BPC-157 Cycle Duration and Time Off: Later TB addition and oral maintenance confound persistent outcomes. The approximately four-hour immediate relief in post 8 is attributed to TB, not BPC, and is excluded from BPC duration. Promotion/procurement replies not reproduced.
Source context — BPC 157, formerly written by me! For all injured athletes!: Forceful protocol claims, guarantees and unsupported safety claims rejected. Only the attributed course/break pattern is retained as discussion.
Source context — Bpc-157 forever?: Book not inspected; attribution does not authenticate the book or a measured human half-life. No no-break safety inference.
Stacks
| Wolverine, GLOW and KLOW | Wolverine combines BPC-157 with TB-500; GLOW adds GHK-Cu and KLOW adds KPV. Premixed ratios can obscure each compound's amount and frequency. |
|---|---|
| Other combinations | Older notes include oral BPC with KPV and co-use with CJC-1295/Ipamorelin, sermorelin or MK-677. Rehab and changes in training often occur too. |
Notes
Combinations make individual effects harder to separate. “Wolverine” means BPC-157 plus TB-500; GLOW adds GHK-Cu and KLOW adds KPV. People also combine these with rehab and altered training. Premixed ratios can make each compound's amount and frequency harder to separate. BPC-157 Cycle Duration and Time Off (Community discussion · Accessed 2026-09-30)
Gut-leaning combos: Oral BPC ± KPV, sometimes other GI peptides; injectable BPC still used by some for gut. [community]
Sleep and recovery combinations: Users also report combining BPC with CJC-1295/Ipamorelin, sermorelin, or MK-677 for sleep and recovery. Those combinations make individual effects difficult to separate. [community]
PT / load management: Logs often describe reduced training loads, physical therapy, sleep and progressive loading alongside BPC. These changes also contribute to the recovery account. [community]
Source context — BPC-157 Cycle Duration and Time Off: Later TB addition and oral maintenance confound persistent outcomes. The approximately four-hour immediate relief in post 8 is attributed to TB, not BPC, and is excluded from BPC duration. Promotion/procurement replies not reproduced.
Watch for
| Mood and physical symptoms | Logs include anxiety, emotional flatness or detachment, headache, nausea and palpitations. One stomach-discomfort account began within 20 minutes and lasted 30–60 minutes. |
|---|---|
| Product and immune-reaction concerns | A label cannot verify vial contents. The saved FDA context identifies peptide-impurity and immune-reaction concerns with limited route-specific safety information. |
| Tested sport | The saved WADA source names BPC-157 as prohibited at all times under S0; a forum half-life is not a drug-test clearance window. |
Notes
Mood changes and physical symptoms appear in user logs. Reports include anxiety, feeling emotionally flat or detached, headache, nausea and palpitations. One user reported stomach discomfort within 20 minutes lasting 30–60 minutes; that is an adverse-symptom duration, not a benefit window. BPC-157 Log (Completed) (Personal report · Accessed 2026-09-30) · My experience with BPC-157 (Personal report · Accessed 2026-09-30) · Stomach ache from BPC-157? (Personal report · Accessed 2026-09-30)
A product label does not verify what is in the vial. The FDA identifies concerns about peptide impurities and immune reactions, with limited safety information for the proposed routes. Forum speculation about a bad batch cannot establish why a reaction happened. FDA: compounding substances with potential significant safety risks (Official context · Accessed 2026-09-30) · BPC-157 Log (Completed) (Personal report · Accessed 2026-09-30)
Tested sport: prohibited at all times under WADA S0. A forum half-life claim is not a reliable drug-test clearance window. WADA specifically names BPC-157 in its non-approved-substances category. WADA Prohibited List — S0 (Official context · Accessed 2026-09-30)
Source context — BPC-157 Log (Completed): Uncontrolled subjective report; older product, concurrent illness, prior derealization and changing training. Relative page timestamp not converted to an exact date.
Source context — My experience with BPC-157: SSRI co-use and subjective symptoms; cannot establish interaction or causation. Relative dates retained without a fabricated calendar date.
Source context — Stomach ache from BPC-157?: Adverse sensation only; no efficacy-duration inference.
Source context — FDA: compounding substances with potential significant safety risks: Safety context only; not community numerical source, universal legal classification or individualized advice.
Source context — WADA Prohibited List — S0: Sport-rule context, not a detection window.
Full notes
BPC-157 is a synthetic peptide that people discuss for stubborn tendon and joint pain, injury recovery and gut symptoms. The appeal is getting back to normal movement or training. Community reports range from noticeable relief to no change, and some users stop because of unwanted effects.
What people use it for
BPC stands for Body Protection Compound. In peptide communities, it is usually discussed as a recovery compound rather than a muscle-building drug or a pre-workout. People compare pain, stiffness, movement and digestion across a course of use; those reports do not establish that damaged tissue has healed.
- Tendons, joints and old injuries. Shoulder, elbow and ankle accounts describe less pain or easier movement. Rest, physical therapy and changes in training often happen at the same time, so a better week cannot tell us which part helped. Personal report Reddit
- Gut symptoms, especially in oral discussions. Capsule users discuss digestion and gut comfort, but oral reports also include joint and tendon goals. Capsules and injections have different formulations and reported amounts; equal labeled micrograms do not establish equal effects. Personal report Community
Benefits people report
- Less pain in everyday movement. A shoulder log described less day-to-day pain and a return to a shoulder workout. An elbow account described recovering movement over a course. These are self-assessments, not scans or measurements of tissue repair. Personal report AnabolicMinds
- Better gut comfort or easier training. Some oral users describe improved gut symptoms, sleep or ability to exercise. Others notice nothing. The useful comparison is the specific symptom and activity that changed, rather than a general claim that BPC “heals everything.” Personal report Reddit Personal report
Doses people discuss
These are reported amounts, not instructions. mcg means micrograms; 1,000 mcg equals 1 mg. SubQ means an injection beneath the skin.
- SubQ: 250–500 mcg total per day. This is the recurring band in the existing community record, once daily or divided. Inspected examples include 200 mcg once daily and 250 mcg twice daily—the latter totals 500 mcg a day. Community AnabolicMinds Personal report
- Oral: 200–500 mcg per dose, once or twice daily, in existing charts. Other accounts differ: one arginate-capsule user reported 700 mcg once daily, then twice daily (1,400 mcg/day). These are separate reports, not one interchangeable oral/injection range. Community Personal report
- Higher SubQ reports: 750–1,000 mcg total per day. These appear in the existing chronic-tendon and post-operative notes. Higher amounts do not establish greater benefit or a safe ceiling. Community
Half-life
- About 4 hours is a circulated community estimate. It appears in T Nation discussion and a Reddit comment attributing it to a peptide book. Those posts do not supply a measured human clearance study or establish a route-specific half-life. Treat it as a community claim, not a verified human value. T Nation Reddit
Onset: when people notice a change
- A few days in some accounts; 2–3 weeks in others. An abdominal-injection account described forearm improvement after four days. An elbow user first noticed meaningful change in weeks 2–3. One oral arginate account described feeling calmer after six hours and less pain after two days. These are different outcomes, not a guaranteed onset window. AnabolicMinds AnabolicMinds Personal report
Duration: how long a change lasts
- No dependable single-dose benefit duration in these reports. Most logs describe changes during repeated daily use. Some report lasting improvement; others describe aches returning after a switch or continued symptoms. A course lasting weeks is not proof that one dose works for that long. Personal report Reddit AnabolicMinds Personal report
Cycles and time off
- 2–4 weeks for shorter injury blocks; 4–8 weeks or longer for chronic complaints. These are the existing community patterns. One inspected elbow account ran six weeks; another forum user described two or three months. They do not establish an optimal or safe course length. Community AnabolicMinds
- Breaks vary: 2–4 weeks off, equal time off, or stopping when symptoms settle. A forum post describes four weeks on followed by two to four off. Other threads disagree about needing a break at all. Five days on/two off also appears; no shared rule settles the disagreement. Community AnabolicMinds AnabolicMinds Reddit
Good to know
- Mood changes and physical symptoms appear in user logs. Reports include anxiety, feeling emotionally flat or detached, headache, nausea and palpitations. One user reported stomach discomfort within 20 minutes lasting 30–60 minutes; that is an adverse-symptom duration, not a benefit window. Personal report Personal report Personal report Community
- A product label does not verify what is in the vial. The FDA identifies concerns about peptide impurities and immune reactions, with limited safety information for the proposed routes. Forum speculation about a bad batch cannot establish why a reaction happened. Official context Personal report
- Tested sport: prohibited at all times under WADA S0. A forum half-life claim is not a reliable drug-test clearance window. WADA specifically names BPC-157 in its non-approved-substances category. Official context
From community discussion
- Improvement can come with a reason to stop. The shoulder-log author described improvement alongside nausea, palpitations and feeling detached. Another user reported injury and gut improvement but stopped for disabling anxiety while also taking an SSRI. That co-use does not prove a specific interaction. Personal report Personal report
- Oral versus injected is an argument, not a settled ranking. An oral user described better ankle function, then reported aches returning after switching to injections and improvement again after returning to oral. A reply reported no tendon or ligament benefit from the oral product. Different responses do not verify the products or prove which route is better. Reddit
- Near the injury or in the abdomen? Some posters favor injections near a painful area; others report improvement after abdominal SubQ use. The same discussions disagree about morning versus bedtime, split amounts and fasting. Those preferences should not become instructions to inject into a joint or tendon. AnabolicMinds AnabolicMinds
- No change belongs beside the success stories. One person reported no improvement in a foot ligament injury or wrist sprain after 20 days of a BPC/TB blend. Replies suggested more time or a different product, but neither explanation was established. A null result is not automatically a dosing mistake. Personal report
- Combinations make individual effects harder to separate. “Wolverine” means BPC-157 plus TB-500; GLOW adds GHK-Cu and KLOW adds KPV. People also combine these with rehab and altered training. Premixed ratios can make each compound's amount and frequency harder to separate. Community AnabolicMinds
- Forms and labels create practical confusion. Acetate versus arginate, capsules versus sprays, and premixed versus separate vials are recurring debates. The existing notes include nasal reports around 250–500 mcg per spray; that labeled amount is not equivalent to SubQ exposure. Stability and absorption claims from sellers remain claims. Community
- There is no community “BPC blood test” to prove recovery. The existing record discusses inflammation markers and general blood panels, but people mainly compare symptoms and movement. A normal panel, pain relief or a “research use” label cannot establish that an injury has healed or a product is safe. Community
Context behind the half-life claims
Half-life means how long the amount being measured takes to fall by half. It is different from how long pain relief, a side effect or recovery lasts.
- The measured figures in the original notes are animal results. The 2022 rat/dog study reported parent-peptide plasma half-lives of 15.2 minutes in rats given IV, 7.87–29.7 minutes in rats given IM, and 5.3 minutes in dogs given IV. IV is into a vein; IM is into muscle. These do not establish a human oral or SubQ value and are not used for the community quick answer above. Animal context